Summary & Overview
HCPCS G9803: Beta-Blocker Prescription 135 Days Post-AMI
HCPCS Level II code G9803 identifies patients discharged after acute myocardial infarction (AMI) who were prescribed beta-blocker therapy for at least 135 days within a 180-day measurement interval. As a performance measure, it tracks adherence to guideline-based secondary prevention that can reduce recurrent cardiac events and improve long-term outcomes. National attention to such measures stems from their role in quality reporting, value-based payment programs, and transitions-of-care initiatives. Key payers addressed in analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent and service setting, an explanation of payer coverage patterns and implications for quality reporting, and a summary of typical documentation and measurement considerations related to post-discharge beta-blocker prescribing. The publication covers where this measure applies in care pathways (hospital discharge through outpatient follow-up and pharmacy fulfillment), common operational challenges in capturing the measurement interval, and the policy context that makes the metric relevant for national quality programs. Data not available in the input for specific payor rates, associated taxonomies, and ICD-10 mappings is noted where applicable.
Billing Code Overview
HCPCS Level II code G9803 denotes a quality measure for patients discharged after acute myocardial infarction (AMI) who were prescribed beta-blocker therapy for at least 135 days within the 180-day measurement interval. This measure represents prescription and post-discharge medication management aimed at secondary prevention following AMI.
-
Service type: Post-discharge medication management and outpatient prescription follow-up
-
Typical site of service: Outpatient pharmacy fulfillment and ambulatory follow-up visits
Clinical & Coding Specifications
Clinical Context
A 62-year-old male is discharged after hospitalization for acute myocardial infarction (AMI) and is prescribed a beta-blocker intended to be taken daily. The discharge summary documents initiation of a guideline-directed beta-blocker and provides a 90-day prescription with two refills to achieve at least 135 days of therapy within the 180-day measurement interval post-discharge. The clinical workflow includes inpatient reconciliation of home medications, discharge counseling by the cardiology team and case management, electronic prescription transmission to the patient’s preferred pharmacy, and scheduled follow-up with the outpatient cardiology or primary care clinic within 7–14 days. Pharmacy refill monitoring and documentation in the electronic health record (EHR) confirm adherence across the 180-day window. Typical site of service is inpatient acute care for the initial AMI hospitalization and outpatient clinic or retail pharmacy for ongoing medication management. Common payors for claims adjudication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work beyond usual service is documented (rare for this measure, e.g., extensive medication reconciliation education). |
23 |